inclusion criteria: 1. healthy male or female volunteer, aged 18-60 years. 2. bmi (quetelet index) in the range 18.0-30.9 kg/m2. 3. able to understand the nature of the trial and any hazards of participating in it. ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire trial. 4. willingness to give written consent to participate after reading the information and consent form, and after having the opportunity to discuss the trial with the investigator or their delegate. 5. agree to follow the contraception requirements of the trial 6. agree not to donate blood or blood products during the study and for up to 3 months after the administration of the trial medication. 7. spirometry readings (fev1 and fvc) to be ≥ 80% of predicted value at the screening visit, calculated using national health and nutrition examination survey (nhanes) reference. if a subject's fev1 or fvc is outside that range at the screening visit, the test may be repeated once on another day. 8. registered with a general practitioner (gp) in the uk (part a only). 9. willingness to give written consent to have data entered into the overvolunteering prevention system (tops).

inclusion criteria: 1. healthy male or female volunteer, aged 18-60 years. 2. bmi (quetelet index) in the range 18.0-30.9 kg/m2. 3. able to understand the nature of the trial and any hazards of participating in it. ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire trial. 4. willingness to give written consent to participate after reading the information and consent form, and after having the opportunity to discuss the trial with the investigator or their delegate. 5. agree to follow the contraception requirements of the trial 6. agree not to donate blood or blood products during the study and for up to 3 months after the administration of the trial medication. 7. spirometry readings (fev1 and fvc) to be ≥ 80% of predicted value at the screening visit, calculated using national health and nutrition examination survey (nhanes) reference. if a subject's fev1 or fvc is outside that range at the screening visit, the test may be repeated once on another day. 8. registered with a general practitioner (gp) in the uk (part a only). 9. willingness to give written consent to have data entered into the overvolunteering prevention system (tops).

inclusion criteria: healthy male or female volunteer, aged 18-60 years. bmi (quetelet index) in the range 18.0-30.9 kg/m2. able to understand the nature of the trial and any hazards of participating in it. ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire trial. willingness to give written consent to participate after reading the information and consent form, and after having the opportunity to discuss the trial with the investigator or their delegate. agree to follow the contraception requirements of the trial agree not to donate blood or blood products during the study and for up to 3 months after the administration of the trial medication. spirometry readings (fev1 and fvc) to be ≥ 80% of predicted value at the screening visit, calculated using national health and nutrition examination survey (nhanes) reference. if a subject's fev1 or fvc is outside that range at the screening visit, the test may be repeated once on another day. registered with a general practitioner (gp) in the uk (part a only). willingness to give written consent to have data entered into the overvolunteering prevention system (tops).

inclusion criteria: healthy male or female volunteer, aged 18-60 years. bmi (quetelet index) in the range 18.0-30.9 kg/m2. able to understand the nature of the trial and any hazards of participating in it. ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire trial. willingness to give written consent to participate after reading the information and consent form, and after having the opportunity to discuss the trial with the investigator or their delegate. agree to follow the contraception requirements of the trial agree not to donate blood or blood products during the study and for up to 3 months after the administration of the trial medication. spirometry readings (fev1 and fvc) to be ≥ 80% of predicted value at the screening visit, calculated using national health and nutrition examination survey (nhanes) reference. if a subject's fev1 or fvc is outside that range at the screening visit, the test may be repeated once on another day. registered with a general practitioner (gp) in the uk (part a only). willingness to give written consent to have data entered into the overvolunteering prevention system (tops).

inclusion criteria: 1. healthy male or female volunteer, aged 18-60 years. 2. bmi (quetelet index) in the range 18.0-30.9 kg/m2. 3. able to understand the nature of the trial and any hazards of participating in it. ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire trial. 4. willingness to give written consent to participate after reading the information and consent form, and after having the opportunity to discuss the trial with the investigator or their delegate. 5. agree to follow the contraception requirements of the trial 6. agree not to donate blood or blood products during the study and for up to 3 months after the administration of the trial medication. 7. spirometry readings (fev1 and fvc) to be ≥ 80% of predicted value at the screening visit, calculated using national health and nutrition examination survey (nhanes) reference. if a subject's fev1 or fvc is outside that range at the screening visit, the test may be repeated once on another day. 8. registered with a general practitioner (gp) in the uk (part a only). 9. willingness to give written consent to have data entered into the overvolunteering prevention system (tops).

inclusion criteria: 1. healthy male or female volunteer, aged 18-60 years. 2. bmi (quetelet index) in the range 18.0-30.9 kg/m2. 3. able to understand the nature of the trial and any hazards of participating in it. ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire trial. 4. willingness to give written consent to participate after reading the information and consent form, and after having the opportunity to discuss the trial with the investigator or their delegate. 5. agree to follow the contraception requirements of the trial 6. agree not to donate blood or blood products during the study and for up to 3 months after the administration of the trial medication. 7. spirometry readings (fev1 and fvc) to be ≥ 80% of predicted value at the screening visit, calculated using national health and nutrition examination survey (nhanes) reference. if a subject's fev1 or fvc is outside that range at the screening visit, the test may be repeated once on another day. 8. registered with a general practitioner (gp) in the uk (part a only). 9. willingness to give written consent to have data entered into the overvolunteering prevention system (tops).